Immuneering (NASDAQ:IMRX) Rating Increased to Strong-Buy at Chardan Capital

Key Points

• Chardan Capital upgraded Immuneering to “strong buy,” while analysts’ overall consensus remains “Buy” with an average price target of $17.57. Ratings are mixed, including recent “outperform,” “buy,” “overweight,” and “sell” opinions.
• Immuneering shares opened at $4.39, compared with a 52-week range of $2.90 to $10.08, giving the company a market capitalization of approximately $284 million.
• The clinical-stage biotech reported a quarterly loss of $0.27 per share, slightly worse than the $0.26 consensus estimate, on $0.36 million in revenue. Its lead candidate, IRX-2, is in Phase 2 trials for painful diabetic peripheral neuropathy.

Immuneering (NASDAQ:IMRX - Get Free Report) was upgraded by stock analysts at Chardan Capital to a "strong-buy" rating in a report released on Monday,Zacks.com reports.

Several other equities research analysts have also recently commented on IMRX. Oppenheimer reissued an "outperform" rating on shares of Immuneering in a research report on Monday, June 1st. Needham & Company LLC raised their price objective on Immuneering from $11.00 to $18.00 and gave the company a "buy" rating in a report on Monday, July 20th. Wall Street Zen downgraded Immuneering from a "hold" rating to a "sell" rating in a research report on Monday, July 20th. Weiss Ratings reissued a "sell (d-)" rating on shares of Immuneering in a research note on Wednesday, June 24th. Finally, Cantor Fitzgerald began coverage on shares of Immuneering in a research note on Wednesday, July 8th. They issued an "overweight" rating and a $17.00 price target for the company. Two equities research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Buy" and an average price target of $17.57.

Immuneering Price Performance

IMRX stock opened at $4.39 on Monday. The stock has a market capitalization of $284.03 million, a P/E ratio of -3.75 and a beta of 0.43. The business has a 50-day moving average of $4.60 and a 200-day moving average of $4.98. Immuneering has a fifty-two week low of $2.90 and a fifty-two week high of $10.08.

Immuneering (NASDAQ:IMRX - Get Free Report) last announced its earnings results on Wednesday, August 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.26) by ($0.01). The company had revenue of $0.36 million during the quarter. Equities analysts expect that Immuneering will post -1.09 EPS for the current year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Caitong International Asset Management Co. Ltd bought a new stake in shares of Immuneering during the fourth quarter worth approximately $33,000. Levin Capital Strategies L.P. acquired a new position in shares of Immuneering in the first quarter valued at approximately $53,000. Mercer Global Advisors Inc. ADV bought a new position in shares of Immuneering during the third quarter worth approximately $70,000. SummitTX Capital L.P. bought a new position in shares of Immuneering during the fourth quarter worth approximately $69,000. Finally, Ausdal Financial Partners Inc. acquired a new stake in Immuneering during the 4th quarter worth approximately $72,000. 67.65% of the stock is owned by institutional investors.

Immuneering Company Profile

Immuneering Nasdaq: IMRX is a clinical-stage biopharmaceutical company leveraging artificial intelligence and its proprietary RABIT (Repurposing and Accelerating Biotechnology Tools) platform to design and optimize small-molecule and peptide therapies. By analyzing large-scale biomedical datasets, Immuneering's machine learning algorithms identify novel drug–target interactions, repurpose existing drug scaffolds and accelerate lead candidate selection. The company's AI-driven approach aims to reduce development timelines and improve therapeutic profiles in areas of high unmet medical need.

The company's lead program, IRX-2, is a small-molecule candidate currently in Phase 2 clinical trials for the treatment of painful diabetic peripheral neuropathy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source